SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (âRAPTâ or the âCompanyâ), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the second quarter and six months ended June 30, 2025.
Related Questions
Are there any regulatory or reimbursement risks highlighted in the MD&A that could impact the company's longâterm prospects?
Were there any significant changes in RAPT's operating expenses, R&D spend, or SG&A costs relative to prior periods?
Did the company announce any new partnerships, licensing deals, or collaborations that could affect future revenue streams?
How did cash and cash equivalents change during the quarter, and what is the projected runway given the current burn rate?
What were RAPT Therapeutics' revenue and net loss for Q2 2025 and the sixâmonth period, and how do these figures compare to consensus estimates?
What is the status of the company's pipeline, including any Phase 2/3 trial initiations or terminations, and how might this affect future cash requirements?
What was the market reaction to the earnings release (preâmarket/afterâhours trading), and are there any notable changes in shortâinterest or institutional ownership?
How does RAPT's valuation metrics (e.g., EV/Revenue, P/E, P/S) after the earnings release compare to its direct competitors in the immunology space?
What milestones were achieved in the company's clinical programs during the quarter, and are there any upcoming data readouts that could move the price?
Did the company provide any updated guidance for Q3 2025 or the fullâyear 2025 outlook, and what are the implications for the stock?